Search Results
Your search for The A,The A matches 32372 pages
Showing 27851 - 27900First Randomized Trial to Show Benefit of Tyrosine Kinase Inhibitor in Newly Diagnosed Acute Myeloid Leukemia
Sorafenib (Nexavar) added to chemotherapy improved event-free survival and relapse-free survival in younger patients with acute myeloid leukemia, according to results of the randomized, controlled phase II SORAML trial.1 However, no significant improvement in overall survival has been seen to ...
Expert Point of View: David Ilson, MD
David Ilson, MD, of Memorial Sloan Kettering Cancer Center in New York, criticized the trial presented by Dr. Penniment at the 2015 Gastrointestinal Cancers Symposium for lacking a chemotherapy-alone arm. “Chemotherapy alone, in phase III trials, has achieved dysphagia relief in 70% of patients,”...
Radiotherapy Alone as Effective as Chemoradiation Therapy in Palliation of Dysphagia in Patients With Advanced Esophageal Cancer
Palliation of dysphagia associated with advanced esophageal cancer can be effectively accomplished with radiotherapy alone, without the addition of chemotherapy, according to a multinational phase III study presented at the 2015 Gastrointestinal Cancers Symposium.1 “There was no significant...
FOLFIRINOX Plus Radiation Renders Some Locally Advanced Pancreatic Cancer Patients Resectable
Investigators from Moffitt Cancer Center in Tampa, Florida, have reported an approach to pancreatic cancer that downstages some locally advanced patients to borderline resectable status and achieves a negative surgical margin rate exceeding 96%. The study earned a Merit Award at the 2015...
Pancreatic Cancer: Latest Drug Development Hits and Misses
Targeting one of the deadliest cancers and seeking to fill an unmet need, drug development in pancreatic cancer is an area of high interest. This was certainly the case at the 2015 Gastrointestinal Cancers Symposium, where results were impressive for some novel agents but disappointing for several...
Surgery Plus Immunotherapy Improves Survival in Melanoma Patients With Gastrointestinal Metastases
When melanoma patients develop metastases to the gastrointestinal (GI) tract or pancreas, resection of these lesions may improve survival, according to two single-institution studies presented at the 2015 Gastrointestinal Cancers Symposium. In a study that earned a Merit Award, researchers reported ...
Statement from the NBPAS
The National Board of Physicians and Surgeons (NBPAS) President Paul Teirstein, MD, released his own statement shortly after Dr. Baron’s letter was released: “ABIM’s recent press release is clearly a step in the right direction. Suspending the practice assessment and patient safety requirements of...
ASCO President on ABIM Decision
Peter Paul Yu, MD, FACP, FASCO, ASCO President, made the following remarks following ABIM’s recent announcement concerning maintenance of certification: “Last year, the American Board of Internal Medicine (ABIM) released a new process for maintenance of certification (MOC) that many physicians felt ...
ABIM President Richard J. Baron, MD, Announces Immediate Changes to Maintenance of Certification Program
The American Board of Internal Medicine (ABIM) announced substantial changes to its Maintenance of Certification (MOC) program and indicated a desire to work more closely with the internal medicine community. ABIM President and CEO Richard J. Baron, MD, MACP, reached out to diplomates via e-mail to ...
Translational Research: Under Assault From the Bottom Line
One of the disheartening aspects of becoming a senior medical administrator is that you have the opportunity to view the health-care system from two sides. From the Presidential suite, it is clear that there is increasing chaos in health care in the United States, characterized by blowouts of...
Expert Point of View
Commenting on the RAISE study at a press briefing held during the 2015 Gastrointestinal Cancers Symposium, moderator Smitha S. Krishnamurthi, MD, Associate Professor of Medicine at Case Western Reserve University School of Medicine, Cleveland, acknowledged that improvements of 1 to 2 months in...
Ramucirumab Added to FOLFIRI Yields Results Similar to Bevacizumab or Aflibercept in Second‑Line Colorectal Cancer
The phase III international RAISE trial found that ramucirumab (Cyramza) extends survival when given with chemotherapy to metastatic colorectal cancer patients who progress on treatment,1 but some experts commented that “financial toxicity” might be an issue, given the modest benefit. “The RAISE...
Cutaneous Adverse Effects Associated With Tyrosine Kinase Inhibitors May Impact Quality of Life and Adherence to Treatment
Tyrosine kinase inhibitors “are associated with numerous adverse effects, many of which are cutaneous and can affect patients’ quality of life and impede their adherence to long-term treatment,” National Cancer Institute (NCI) investigators concluded after studying the adverse effects of the...
Racial Disparities in Survival Related More to Health Differences at Diagnosis Than to Subsequent Treatment
The persistent disparity in colon cancer survival by race seemed to be related more to differences in health at diagnosis than to differences in subsequent treatment, according to an analysis of data from the Survey, Epidemiology, and End Results (SEER)–Medicare database. “Our study suggests that...
High-Quality Diet Before Ovarian Cancer Diagnosis May Lengthen Survival
An overall high-quality diet at least 12 months before a diagnosis of ovarian cancer “was associated with a statistically significant 27% lower risk of death after ovarian cancer,” an analysis of dietary data from the Women’s Health Initiative showed. The protective effect was strongest among women ...
Dianne Knight, MD, Awarded Fellow Status from the American Academy of Hospice and Palliative Medicine
Dianne Knight, MD, Physician in the Supportive Care Medicine Department at Moffitt Cancer Center, has been honored with the designation of Fellow of the American Academy of Hospice and Palliative Medicine. The Academy is the professional organization for physicians and other health care...
If Measles Was Declared ‘Eliminated’ in 2000, Why the Outbreak?
In 2000, measles was declared eliminated from the United States,” according to the Centers for Disease Control and Prevention (CDC). That statement appeared in the same document reporting a large multistate outbreak of measles linked to an amusement park in California and that “has spread to more...
Expect Questions About Measles From Parents of Children With Cancer
With the large outbreak of measles that has spread to more than a dozen states, questions from parents of children with cancer should be expected and encouraged. Parents should “talk to their physician about what the level of risk may be for their child who is undergoing cancer treatment (or has...
Measles Presents Greater Risks in Children Being Treated for Cancer
Measles outbreaks in the United States during 2014 and early 2015 have yielded an unprecedented number of cases nationwide, raising concerns about the threat measles poses to cancer patients (especially children) who may be at risk for severe complications and even death due to measles infection....
Lee W. Wattenberg, MD, the ‘Father of Chemoprevention’ Dies at 92
One of the early giants in the field of cancer prevention, Lee W. Wattenberg, MD, died on December 9, 2014, at the age of 92. A native New Yorker, Dr. Wattenberg received his BS from City College of New York in 1941 and then went on to attain his medical degree from the University of Minnesota...
Lee Schwartzberg, MD, Appointed Vice Chairman of Caris Centers of Excellence Network
Caris Life Sciences, a biosciences company focused on precision medicine, announced the designation of West Cancer Center in Memphis as a Center of Excellence site in the Caris Centers of Excellence for Precision Medicine Network. Additionally, Lee S. Schwartzberg, MD, Medical Director of West...
Theodore Lawrence, MD, PhD, Named Director of University of Michigan Comprehensive Cancer Center
Theodore S. Lawrence, MD, PhD, has been named Director of the University of Michigan Comprehensive Cancer Center. Dr. Lawrence succeeds Max S. Wicha, MD, who founded the Cancer Center 27 years ago. “This is a tremendous program, with talented and dedicated faculty and staff, a terrific research...
John A. Hartford Foundation Names Terry Fulmer, PhD, RN, as New President
The John A. Hartford Foundation announced that Terry Fulmer, PhD, RN, FAAN, University Distinguished Professor and Dean of the Bouvé College of Health Sciences at Northeastern University, will become its new President. Dr. Fulmer, who is also Professor of Public Policy and Urban Affairs in the...
Thomas J. Rutherford, MD, PhD, Named Network Physician Director of Cancer Services at Western Connecticut Health Network
Western Connecticut Health Network (WCHN) has named gynecologic oncologist Thomas J. Rutherford, MD, PhD, an expert in the area of ovarian cancer, as the Network Physician Director of Cancer Services. As Director, Dr. Rutherford will create a new model of cancer delivery in the dynamic environment ...
ASCO Commends Margaret Hamburg, MD, for Leadership as FDA Commissioner
ASCO expresses deep gratitude to Margaret Hamburg, MD, for her 6 years of vision and progress as Commissioner of the U.S. Food and Drug Administration (FDA). Dr. Hamburg, one of the longest-serving FDA commissioners, leaves a legacy of important advances in regulatory science and medicine. The...
Patient Guides Available Through ASCO University Bookstore
ASCO Answers: Managing the Cost of Cancer Care explains the various costs associated with cancer treatment, including health-care coverage through the Affordable Care Act. It also provides a list of financial resources available to help offset expenses related to care and tips for organizing...
Cancer Was My Wake-Up Call to a Healthier Life
I come from strong physical stock and inherited a sort of “tough it out mentality” when it comes to coping with the usual aches and pains that creep up as you age. So by the time I realized that my legs had become so swollen and my breathing so labored it was difficult for me to walk, I could...
The Journey From Book to Film
Soon after publication of The Emperor of All Maladies: A Biography of Cancer (Scribner) in 2010, the book’s author Siddhartha Mukherjee, MD, PhD, received a call from Laura Ziskin, a film producer and cofounder of Stand Up To Cancer, who was interested in obtaining the film rights to Dr....
Telling the Story of Cancer
Acclaimed documentarian Ken Burns (The Civil War, Baseball, Jazz, The Central Park Five, and The Roosevelts: An Intimate History) has been making films for more than 35 years. His most recently completed project, scheduled to air on PBS this spring, is Ken Burns Presents Cancer: The Emperor of All...
Bringing the History of Cancer to Film
Ken Burns Presents Cancer: The Emperor of All Maladies, A Film by Barak Goodman will be broadcast on PBS on March 30, March 31, and April 1. Check local listings for broadcast times. Like the book it’s based on, the television documentary Ken Burns Presents Cancer: The Emperor of All Maladies, A...
Texas Center for Proton Therapy Names Andrew K. Lee, MD, Medical Director
Andrew K. Lee, MD, has been named Medical Director of the Texas Center for Proton Therapy. Dr. Lee launched proton therapy treatment at The University of Texas MD Anderson Cancer Center almost 9 years ago, treating the facility’s first proton therapy patient in 2006. In his new role, Dr. Lee will...
Douglas R. Lowy, MD, Receives Harrington Prize for Innovation in Medicine
The second annual Harrington Prize for Innovation in Medicine has been awarded to oncologist/researcher Douglas R. Lowy, MD, Chief of the Laboratory of Cellular Oncology and Deputy Director of the National Cancer Institute. The Harrington Prize for Innovation in Medicine, established in 2014 by...
International Marketing Expert Claire Huang Appointed to Conquer Cancer Foundation Leadership
The Conquer Cancer Foundation of ASCO has announced the appointment of Claire Huang to its Board of Directors. Ms. Huang, an established leader in the fields of marketing, communications, and brand management, will serve a 3-year term. “It is a privilege to welcome Claire Huang to the Conquer...
Palbociclib as Initial Endocrine-Based Therapy in Postmenopausal Women With Metastatic Breast Cancer
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On February 3, 2015, palbociclib (Ibrance) was granted...
Kay Research and Care Center Opens at St. Jude Children’s Research Hospital
St. Jude Children’s Research Hospital in Memphis has officially opened the Kay Research and Care Center. The new $198 million center houses the Eric Trump Foundation Surgery and ICU Center, and the Marlo Thomas Center for Global Education and Collaboration. The St. Jude Red Frog Events Proton...
Improving the Quality of Palliative Care in Oncology
Two years ago, ASCO collaborated with the American Academy of Hospice and Palliative Medicine to develop the Virtual Learning Collaborative, a virtual quality improvement program intended to address the complex care needs of patients with advanced cancer and the care quality for all patients with...
FDA Approves Lenalidomide in Combination With Dexamethasone for Newly Diagnosed Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has expanded the existing indication for lenalidomide (Revlimid) in combination with dexamethasone to include patients newly diagnosed with multiple myeloma. Lenalidomide plus dexamethasone was previously approved in June 2006 for use in multiple myeloma...
FDA Approves Panobinostat Combination for the Treatment of Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has approved panobinostat (Farydak) in combination with bortezomib (Velcade) and dexamethasone for the treatment of patients with multiple myeloma. Panobinostat is the first histone deacetylase (HDAC) inhibitor approved to treat multiple myeloma. It is...
The Current State of Hematologic Malignancies
Due in part to the refinement of bone marrow transplantation and its many innovations, some leukemias that once were death sentences now have cure rates of up to 90%. As research in transplantation and other promising areas accelerates, we are on the verge of breaking new clinical boundaries in...
AAHPM Unveils List of Inspiring Hospice and Palliative Medicine Leaders Under 40
The American Academy of Hospice and Palliative Medicine (AAHPM) has released a list of Inspiring Leaders Under 40 in the field. Eligible candidates were evaluated on involvement in AAHPM, educating others about hospice and palliative medicine, participation in charitable work, mentoring of students ...
MD Anderson Names Patrick Hwu, MD, Head of Cancer Medicine
Patrick Hwu, MD, Chair of Melanoma Medical Oncology and Sarcoma Medical Oncology at The University of Texas MD Anderson Cancer Center, Houston, has been named Division Head of Cancer Medicine. He will take over from Richard Champlin, MD, who has been acting Division Head on an ad interim basis. Dr. ...
American Association for Cancer Research Inducts 2015 Class of Fellows of the AACR Academy
The American Association for Cancer Research (AACR) has announced 11 new fellows of the AACR Academy. The AACR Academy is an entity that recognizes individuals who have made exceptional contributions to cancer research and/or cancer-related biomedical science. Only individuals whose work has had a...
Treating Head and Neck Cancer in 2015
Each year in the United States, about 55,000 people will be diagnosed with head and neck cancer, and of them, about 12,000 will die of the disease. Although advances have been made in the treatment of head and neck cancer, this disease remains persistently problematic, due, in part, to the complex...
Clinically Inappropriate Patient Demands of Oncologists Happen More Infrequently Than Expected
A new study1 conducted at outpatient oncology centers found that only 1% of 5,050 patient-clinician encounters resulted in a clinically inappropriate request, of which very few were complied with by physicians. Ezekiel J. Emanuel, MD, PhD, of the University of Pennsylvania, and colleagues analyzed...
For Hodgkin Lymphoma Patients, It Ain’t Over
With less than 10,000 patients diagnosed with Hodgkin lymphoma each year and a cure rate of approximately 75% to 80%, drug development for this disease was never a priority for pharmaceutical companies. So when the antibody-drug conjugate brentuximab vedotin (Adcetris) was approved by the U.S. Food ...
PD-1 Blockade With Nivolumab Produces High Response Rate in Relapsed/Refractory Hodgkin Lymphoma
Anti–PD-1 antibodies have been shown to be effective in solid tumors. There is evidence that the malignant Reed-Sternberg cells in Hodgkin lymphomas use the programmed cell death protein 1 (PD-1) pathway to evade immune detection, with alterations in chromosome 9p24.1 increasing levels of the PD-1...
MD Anderson Receives $22.3 Million in CPRIT Research Funding
The University of Texas MD Anderson Cancer Center has received more than $22 million in research grants from the Cancer Prevention and Research Institute of Texas (CPRIT). The CPRIT awards will go toward studies in the areas of breast, skin, prostate, pancreas, colon, and lung cancers in adults,...
The Search for Optimal Adjuvant Breast Cancer Chemotherapy: The End of an Era?
Using a complex and innovative study design, Budd and colleagues from the Southwest Oncology Group (SWOG) addressed, in a randomized multicenter trial,1 an issue that has been under evaluation for over 40 years—namely, what are the optimal dose and schedule for adjuvant breast cancer chemotherapy?...
Combination Treatment Every 2 Weeks May Benefit Some Women With High-Risk Early-Stage Breast Cancer
In a phase III trial (SWOG S0221) reported in the Journal of Clinical Oncology, George T. Budd, MD, of Taussig Cancer Center, Cleveland Clinic, and colleagues found no difference in disease-free survival among four different combinations of continuous or every-other-week...
ASCO Collaborates in Launch of Crowd-Sourced Molecular Oncology Tumor Board Series
The ASCO University®, the College of American Pathologists (CAP), and the Association for Molecular Pathology (AMP) recently announced their collaboration to create the Molecular Oncology Tumor Board series, an online and user-driven resource designed to help cancer care providers with the...
